	US 12,377,046 B1
	Delivery system matrices
Mark J. Neveu, Bethel, ME (US)
Assigned to Wellomics LLC, Bethel, ME (US)
Filed by Wellomics LLC, Bethel, ME (US)
Filed on Apr. 24, 2020, as Appl. No. 16/857,865.
Claims priority of provisional application 62/838,260, filed on Apr. 24, 2019.
Int. Cl. A61K 31/7008 (2006.01); A23B 20/10 (2025.01); A23D 7/005 (2006.01); A23D 7/04 (2006.01); A23L 29/231 (2016.01); A23L 29/25 (2016.01); A23L 33/105 (2016.01); A23L 33/125 (2016.01); A23L 33/22 (2016.01); A61K 9/06 (2006.01); A61K 9/107 (2006.01); A61K 47/36 (2006.01)

CPC A61K 9/107 (2013.01) [A23B 20/10 (2025.01); A23D 7/0053 (2013.01); A23D 7/04 (2013.01); A23L 29/231 (2016.08); A23L 29/25 (2016.08); A23L 33/105 (2016.08); A23L 33/125 (2016.08); A23L 33/22 (2016.08); A61K 9/06 (2013.01); A61K 47/36 (2013.01); A23V 2002/00 (2013.01)]

26 Claims

1. A dietary product or oral pharmaceutical comprising an oil-in-water (O/W) emulsion complex comprising a water phase and an oil phase, ascorbyl palmitate, a high hydrophile-lipophile balance (HLB) saponin with a HLB of greater than or equal to 10, and a Glycyrrhiza glabra (licorice) root saponin, wherein the concentration of ascorbyl palmitate is 0.15-4.5 mg/gm, wherein the concentration of the high HLB saponin is 0.01-1.6 mg/gm, and wherein the concentration of Glycyrrhiza glabra root saponin is 0.02-160 mg/gm.